Davies JA - Search Results

1

Engineering Adenoviral Vectors with Improved GBM Selectivity.

Bates EA, Lovatt C, Plein AR, Davies JA, Siebzehnrubl FA, Parker AL. Bates EA, et al. Among authors: davies ja. Viruses. 2023 Apr 28;15(5):1086. doi: 10.3390/v15051086. Viruses. 2023. PMID: 37243172 Free PMC article.

2

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL. Uusi-Kerttula H, et al. Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015. Hum Gene Ther. 2015. PMID: 25919378 Free PMC article.

3

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Uusi-Kerttula H, et al. Viruses. 2015 Nov 24;7(11):6009-42. doi: 10.3390/v7112923. Viruses. 2015. PMID: 26610547 Free PMC article. Review.

4

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL. Uusi-Kerttula H, et al. Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545. Oncotarget. 2016. PMID: 27056886 Free PMC article.

5

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.

Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén G. Man YKS, et al. Among authors: davies ja. Mol Cancer Ther. 2018 Feb;17(2):575-587. doi: 10.1158/1535-7163.MCT-17-0671. Mol Cancer Ther. 2018. PMID: 29367266

6

Ad5_NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL. Uusi-Kerttula H, et al. Among authors: davies ja. Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24. Clin Cancer Res. 2018. PMID: 29798908 Free article.

7

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, Chester JD, Parker AL. Hulin-Curtis SL, et al. Among authors: davies ja. Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29. Oncotarget. 2018. PMID: 29899862 Free PMC article.

8

Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.

Baker AT, Greenshields-Watson A, Coughlan L, Davies JA, Uusi-Kerttula H, Cole DK, Rizkallah PJ, Parker AL. Baker AT, et al. Among authors: davies ja. Nat Commun. 2019 Feb 14;10(1):741. doi: 10.1038/s41467-019-08599-y. Nat Commun. 2019. PMID: 30765704 Free PMC article.

9

Systemic delivery and SPECT/CT in vivo imaging of ¹²⁵I-labelled oncolytic adenoviral mutants in models of pancreatic cancer.

Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J, Halldén G. Stella Man YK, et al. Among authors: davies ja. Sci Rep. 2019 Sep 6;9(1):12840. doi: 10.1038/s41598-019-49150-9. Sci Rep. 2019. PMID: 31492884 Free PMC article.

10

Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor.

Baker AT, Mundy RM, Davies JA, Rizkallah PJ, Parker AL. Baker AT, et al. Among authors: davies ja. Sci Adv. 2019 Sep 4;5(9):eaax3567. doi: 10.1126/sciadv.aax3567. eCollection 2019 Sep. Sci Adv. 2019. PMID: 31517055 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

590 results

Search Page

Filters